M. Hellmann

Oncology · 2015–2021

A researcher in the Science corpus: 32 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom M. Hellmann trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. S. Spranger
  2. J. Wolchok
  3. M. Reck
  4. C. Robert

Who trusts M. Hellmann overall

  1. Timothy A. Chan

Papers from M. Hellmann's perspective

Ordered by how strongly the researchers M. Hellmann trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
  2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  3. PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)
  4. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial (The Lancet)
  5. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)
  6. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)
  7. PD-1 blockade induces responses by inhibiting adaptive immune resistance (Nature)
  8. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma (New England Journal of Medicine)
  9. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing (Nature Biotechnology)
  10. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell)

Their papers